Our dextran drug delivery system was first developed at the Faculty of Chemical and Process Engineering of the Warsaw University of Technology in the Biomedical Engineering Laboratory established by Dr. Ciach decided to commercialize the technology and founded NanoVelos. Technology based on polysaccharide nanoparticles is orginal solution patented by NanoVelos SA In vitro experiments: Assesment of cell viability (MTT assay, HeLa cells etc.) demonstrates that examined drugs released from nanoparticles retains its potential to induce cell death. The main goals of those studies is to collect the data providing submission to FDA or EMA. These interventions may be medical products, such as drugs or devices; procedures; or changes to participants’ behavior, such as diet. When a new product or approach is being studied, it is not usually known whether it will be helpful, harmful, or no different than available alternatives. The EMA (European Medicines Agency), is the European Union’s equivalent to the U.S. Treatments are not one-size-fits-all, that’s why we focus on various areas.
Warsaw, Poland
Founded in 2013
1-10 Employees
Working industry
Pharmaceuticals
Type of company
Manufacturer, Service provider
Ownership structure
Privately Held
Locations
1 Headquarter
Number of services
2 Services
Specialised areas
nanotechnology, drug nanodelivery, supergenerics, Delivery, Pharmaceuticals, Pharmaceutical, oncology, Health Care
NanoVelos offers a wide range of products and services
Service
Our Services in Nanotechnology | NanoVelos | Drug Delivery Systems
Go to product >
Service
Our services PL | NanoVelos | Drug Delivery Systems
Go to product >
An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself
Country:
Poland
Overall risk estimation:
Low
The ESG Data of countries are based on public sources
Environment
B
Grade (A-E)
View details
Social
B
Grade (A-E)
View details
Governance
B
Grade (A-E)
View details
Get insights into the use cases of NanoVelos
Use case
Projects | NanoVelos | Drug Delivery Systems
Partners Grants Preclinical and clinical studies of innovative nanoformulations of anticancer drugs POIR.01.01.01-00-0021/16-00 In this project NanoVelos plans to carry out industrial research aimed at encapsulation of number of chemotherapeutic agents used already in a clinic into proprietary nanoparticles. Of the newly synthesized nanoformulations we will select those which will …
NanoVelos operates in 1 country around the world
Get an overview of the locations of NanoVelos
Location
Country
State
City
Headquarter
Poland
Masovian Voivodeship
Warsaw
Some frequent questions that have been asked about NanoVelos
Where is NanoVelos located?
The company headquarter of NanoVelos is located in Warsaw, Masovian Voivodeship, Poland. It's worth noting, that the company may have more locations
How many employees does NanoVelos approximately have?
As of the latest available information NanoVelos has around 1-10 employees worldwide.
When was NanoVelos founded?
NanoVelos was founded in 2013
In which industries does NanoVelos mainly work?
The company NanoVelos has it's main focus in the industries of Pharmaceuticals
Check out some interesting alternative companies to NanoVelos
Optima Nanomed Limited
London, United Kingdom
1-10 Employees
-
We are re-imagining and re-shaping drug delivery by commercialising top-notch principles from academia, minimising drug development costs and time to market; and eliminating side effects. We are developing nanomaterials for improved drug delivery into tissues that hard to target and penetrate by conventional drugs and methods. We are leveraging from years of experience and expertise. We are using proprietary technology to develop smart programmable nanomaterials. An inevitable outcome of taking a drug are side effects due to poor drug delivery - an example are cancer patients who often lose their hair even their lives! Because the drug is poorly delivered to both healthy and cancer cells leading to toxicity. Poor drug delivery leads to toxicity, side effects, the need of higher dosages and major capital losses. At Optima Nanomed we believe now is the time to act.
AQUA Biomaterials
San Diego, United States
1-10 Employees
2014
This product is the next generation, animal-free version of the heparin nanoparticles Dr. Drug Delivery - small molecule, DNA/RNA, antibody, conjugates and fragments. Objective: Develop system to deliver large, hydrophilic molecules such as hyaluronic acid into human skin. Diffusion coefficient of hyaluronic acid enhanced 2.5-fold in (+/+) over current marketed products (O/W and -/+). Our technology delivers more hyaluronic acid to the skin than what is lost on a daily basis. Conclusion: A transdermal delivery nanotechnology has been developed in which the diffusion of the molecule through the stratum corneum is dependent on the diameter of the internal phase nanogel, not on the molecular weight of the individual molecule. We offer contract services to customers who seek expert technical advice, product prototyping, and process development for projects including:. We also manage early stage research and development projects through pilot production and pre-clinical testing.
Westwood Bioscience Inc
Los Angeles, United States
1-10 Employees
2018
Nanomedicine is a newly evolving field in which the functions and features of nanoscale objects and systems are used for improved diagnostics, imaging, therapeutics and regenerative medicine.Nanotherapeutics include the use of nanocarriers for drug delivery, with the potential to improve the pharmacokinetics, biodistribution, tissue concentrations and efficacy over the free drug. In addition, encapsulated drug delivery can also reduce the systemic biodistribution and toxicity of potentially hazardous drugs such as chemotherapeutics.The Silicasome is an example of an encapsulated nanocarrier, which is comprised of a mesoporous silica nanoparticle core with a lot of drug packaging space, and surrounded by a lipid bilayer. Westwood Bioscience, Inc., incorporated in 2017, are developing a new nanocarrier technology for improved delivery of chemotherapeutic agents to pancreas and colon cancer tuned to achieve improved efficacy, while reducing toxicity.Work led by Drs. This development has attracted significant attention in the field of pancreas cancer chemotherapy, as the Westwood nanocarrier is capable of delivering a single or ratiometric combination of chemotherapeutic agents to the cancer site, with the ability to overcome the drug resistant in stroma, improve efficacy and improve the toxicity over other nanocarriers used for treating this disease.
NanoSiliCal Devices Srl
Rende, Italy
1-10 Employees
2014
We produce highly intelligent, multifunctional, mesoporous silica micro and nano-systems to be exploited in target therapy. Our products technology is based on science of materials, providing nanostructured particles that can be administered intravenously, and, through the bloodstream, they can reach cancer cells, interact with them through a biological process and release a drug within. NanoSiliCal Devices is a spin-off at the University of Calabria, founded in 2014 by the research team made up by Prof. It aims to develop nanostructured products that may be exploited as smart anticancer therapies, basing its activities on the results of experimental studies, gained in the last 10 years, that haveled to several International Patent Applications and publications on international journals with high impact factor. Research and development activities are the aim of the innovative nature of NanoSiliCal Devices. NanoSiliCal Devices is the result of several studies based on properties, synthesis, characterization and biological validation of mesoporous silicas.These studies involve a modular method of synthesis of mesoporous silica based micro-and nano-systems that could be used for drug delivery. This is an excellent drug delivery system based on Receptor-specific ligand on the external surface and drug inside the pores. The main application of our products is the targeted chemotherapy, whose main purpose is to reduce drug doses, to improve therapeutic efficacy and to reduce toxic and side effects.
Nanoform
Helsinki, Finland
11-50 Employees
2015
Nanoform works to improve the lives of patients globally by overcoming drug development and delivery challenges through our game-changing technologies and novel formulation capabilities. We have a dedicated, multi-disciplinary team with a combined experience of launching 100+ medicines. TargTex Ceo João Seixas discusses the value Nanoform’s CESS® technology delivered for TargTex’s drug candidate targeting glioblastoma. At Nanoform, we are proud to reflect our dedication to sustainability in our cutting-edge nanoparticle engineering processes. Discover how we are driving sustainability in the pharma industry in our Ebook.
DelSiTech Ltd
Turku, Finland
11-50 Employees
2001
DelSiTech is the leading technology specialist in biodegradable silica-based controlled release of small molecule drugs, biopharmaceuticals and viral vectors. DelSiTech currently holds technology collaboration and licensing agreements with AstraZenega, Anticancer Bioscience, Bayer Pharma AG, Innovare R&D, Iveric Bio, Optifye Therapeutics, Unitaid, MedImmune and Solani Therapeutics Ltd and evaluation agreements with several pharma, animal health and biotech companies. We focus on parenteral and local administration of drug products. Products with high commercial potential – DelSiTech’s own drug product for high unmet clinical and commercial needs. Innovative delivery technology – Silica-based drug delivery for controlled release of small molecules and bioparmaceuticals. New nanotech solutions in drug delivery – DelSiTech is a world technology leader in advanced biodegradable silica based controlled release materials. The natural solution for your drug delivery needs – We help you to get the most out of your innovations. The preferred method for controlled delivery of small molecule drugs, including poorly or highly soluble compounds.